October 1, 2003 |
Vaccine developer VaxGen Inc. said it was awarded an $80.3-million contract from the National Institutes of Health for development of an experimental anthrax vaccine. The three-year contract could pave the way for a significantly larger contract for a national stockpile of anthrax vaccine, the San Diego-based company said. The company's shares, which have fallen 31% this year, rose 7 cents to $12.07 on Nasdaq before the contract award was announced.
February 25, 2003 |
Shares in biotechnology company VaxGen Inc. plunged 47% on Monday after the company revealed that its five-year, $100-million trial of an experimental AIDS vaccine didn't protect people from the virus. The failure of the largest human trial yet for an AIDS vaccine throws VaxGen's future in question. The company, based in Brisbane, Calif., has no licensed products and only about seven months of cash remaining.
January 25, 2003 |
Shares of VaxGen Inc., a tiny Northern California biotechnology company racing to develop the first successful AIDS vaccine, plummeted Friday after billionaire Paul Allen revealed that he had reduced his once-substantial stake to less than 5%. Allen's smaller stake added to speculation that VaxGen's experimental vaccine doesn't protect users from the fatal disease. But Jim Key, a company spokesman, said results of a closely watched drug trial, which ended in December, aren't yet known.
December 17, 2002 |
VaxGen Inc. said Monday that the Food and Drug Administration has agreed to an accelerated review of its experimental HIV vaccine -- news that sent the company's shares up 21%. "This is a significant positive for VaxGen.... Once the applications are filed, the FDA can make a decision in fairly short order," said Anna Kazanchyan, an analyst at Investec Inc., which does not have a banking relationship with VaxGen.
June 4, 1998 |
A California company has received permission from the Food and Drug Administration to conduct the world's first large-scale test of an AIDS vaccine, and company officials said Wednesday they would start offering the vaccine to thousands of healthy U.S. volunteers later this month. The go-ahead represents a major turning point in the agonizingly difficult, decade-long effort to develop and test a vaccine against AIDS.
January 13, 1998 |
VaxGen Inc., a small biotechnology company, has not yet received approval from the Food and Drug Administration to begin human trials of an AIDS vaccine later this year, the company said Monday. The $20-million VaxGen study would involve 7,500 healthy volunteers and would take about three years to complete, company spokeswoman Donna Walters said. If successful, the vaccine could be available to the public early in the next century.
January 11, 1998 |
A small California biotechnology company has engineered the first AIDS vaccine to win federal approval for a large-scale trial in humans, the San Jose Mercury News reported Saturday. The study, which will begin this year, will involve 7,500 healthy volunteers, cost $20 million and take three years. If successful, the vaccine would be made available to the public in the early part of the next century, the paper said. AIDS researchers and activists said the development of the vaccine, produced by VaxGen Inc., is a milestone in the fight against the virus that has killed 11.7 million people worldwide.